Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Change in Receivables (2016 - 2025)

Coherus Oncology's Change in Receivables history spans 12 years, with the latest figure at $8.3 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 114.8% year-over-year to $8.3 million; the TTM value through Dec 2025 reached -$93.6 million, up 37.36%, while the annual FY2025 figure was -$93.6 million, 37.36% up from the prior year.
  • Change in Receivables for Q4 2025 was $8.3 million at Coherus Oncology, up from $4.3 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $75.3 million in Q3 2023 and bottomed at -$76.6 million in Q2 2024.
  • The 5-year median for Change in Receivables is -$6.9 million (2022), against an average of -$7.0 million.
  • The largest annual shift saw Change in Receivables skyrocketed 3084.96% in 2023 before it plummeted 493.2% in 2025.
  • A 5-year view of Change in Receivables shows it stood at -$13.3 million in 2021, then skyrocketed by 240.91% to $18.8 million in 2022, then surged by 134.38% to $44.1 million in 2023, then plummeted by 227.85% to -$56.3 million in 2024, then soared by 114.8% to $8.3 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Change in Receivables are $8.3 million (Q4 2025), $4.3 million (Q3 2025), and -$55.3 million (Q2 2025).